Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.

about

Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.

Item

http://www.wikidata.org/entity/Q54976603

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Apatinib, a novel tyrosine kin ...... nd synergizes with Paclitaxel.

@en

Apatinib, a novel tyrosine kin ...... nd synergizes with Paclitaxel.

@nl

type

Item

label

Apatinib, a novel tyrosine kin ...... nd synergizes with Paclitaxel.

@en

Apatinib, a novel tyrosine kin ...... nd synergizes with Paclitaxel.

@nl

prefLabel

Apatinib, a novel tyrosine kin ...... nd synergizes with Paclitaxel.

@en

Apatinib, a novel tyrosine kin ...... nd synergizes with Paclitaxel.

@nl

P1476

Apatinib, a novel tyrosine kin ...... nd synergizes with Paclitaxel.

@en

P2093

Haifeng Qiu

http://www.w3.org/2001/XMLSchema#string

Jing Li

http://www.w3.org/2001/XMLSchema#string

Mei Tang

http://www.w3.org/2001/XMLSchema#string

Qiuli Liu

http://www.w3.org/2001/XMLSchema#string

Yuan Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters

Global cancer statistics, 2012

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

VEGF targets the tumour cell.

Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer.

Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway

Developments in the systemic treatment of metastatic cervical cancer.

P31

scholarly article

P356

10.1080/15384101.2018.1471315

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29886786

http://www.w3.org/2001/XMLSchema#string

P932

6110593

http://www.w3.org/2001/XMLSchema#string